PaclitaxelAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsCarboplatinDrug Administration ScheduleOvarian NeoplasmsTubulin ModulatorsDrug Resistance, NeoplasmCisplatinInfusions, IntravenousTaxoidsLung NeoplasmsBreast NeoplasmsAntineoplastic AgentsDoxorubicinTreatment OutcomeBridged CompoundsDose-Response Relationship, DrugCarcinoma, Non-Small-Cell LungNeutropeniaTaxusCell Line, TumorTubulinEpothilonesPharmaceutical VehiclesDeoxycytidineDrug SynergismDisease-Free SurvivalMaximum Tolerated DoseArea Under CurveP-GlycoproteinPeripheral Nervous System DiseasesEpirubicinSurvival AnalysisMice, NudeFallopian Tube NeoplasmsMicrotubulesTopotecanVinblastineCombined Modality TherapyNeoplasmsTumor Cells, CulturedApoptosisSurvival RateXenograft Model Antitumor AssaysDrug Resistance, MultipleDrug CarriersNeoplasm StagingDrug Delivery SystemsDrug Screening Assays, AntitumorAntibodies, Monoclonal, HumanizedCyclophosphamidePeritoneal NeoplasmsIfosfamideNanoparticlesNeoplasms, Glandular and EpithelialLeukopeniaHematologic DiseasesFluorouracilGranulocyte Colony-Stimulating FactorAlbuminsThrombocytopeniaCarcinomaPlatinum CompoundsChemotherapy, AdjuvantEstramustineMicellesPolyglutamic AcidInhibitory Concentration 50Chemistry, PharmaceuticalFeasibility StudiesRadiation-Sensitizing AgentsTime FactorsCell SurvivalAdministration, OralAdenocarcinomaCyclosporins